Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 2
2022 6
2023 9
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021.
van Not OJ, van den Eertwegh AJM, Haanen JB, Blank CU, Aarts MJB, van Breeschoten J, van den Berkmortel FWPJ, de Groot JB, Hospers GAP, Ismail RK, Kapiteijn E, Bloem M, De Meza MM, Piersma D, van Rijn RS, Stevense-den Boer MAM, van der Veldt AAM, Vreugdenhil G, Boers-Sonderen MJ, Blokx WAM, Wouters MWJM, Suijkerbuijk KPM. van Not OJ, et al. EClinicalMedicine. 2024 Feb 12;69:102485. doi: 10.1016/j.eclinm.2024.102485. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38370537 Free PMC article.
A prediction model for response to immune checkpoint inhibition in advanced melanoma.
van Duin IAJ, Verheijden RJ, van Diest PJ, Blokx WAM, El-Sharouni MA, Verhoeff JJC, Leiner T, van den Eertwegh AJM, de Groot JWB, van Not OJ, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Haanen JBAG, Hospers GAP, Piersma D, van Rijn RS, van der Veldt AAM, Vreugdenhil G, Wouters MWJM, Stevense-den Boer MAM, Boers-Sonderen MJ, Kapiteijn E, Suijkerbuijk KPM, Elias SG. van Duin IAJ, et al. Among authors: van not oj. Int J Cancer. 2024 May 15;154(10):1760-1771. doi: 10.1002/ijc.34853. Epub 2024 Jan 31. Int J Cancer. 2024. PMID: 38296842
BRAF/MEK inhibitor rechallenge in advanced melanoma patients.
Van Not OJ, van den Eertwegh AJM, Haanen JB, van Rijn RS, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Boers-Sonderen MJ, de Groot JWWB, Hospers GAP, Kapiteijn E, Bloem M, Piersma D, Stevense-den Boer M, Verheijden RJ, van der Veldt AAM, Wouters MWJM, Blokx WAM, Suijkerbuijk KPM. Van Not OJ, et al. Cancer. 2024 May 1;130(9):1673-1683. doi: 10.1002/cncr.35178. Epub 2024 Jan 10. Cancer. 2024. PMID: 38198485
Patient-Reported Outcomes of Medical Tattooing for Capillary Malformations.
Langbroek GB, Felsbourg J, Wolkerstorfer A, Horbach SER, Souisa Kooger L, van Dieren S, van Not OJ, van Not HP, Souisa R, Ubbink DT, van der Horst CMAM. Langbroek GB, et al. Among authors: van not oj. Dermatology. 2023;239(5):768-781. doi: 10.1159/000530609. Epub 2023 Jul 13. Dermatology. 2023. PMID: 37442102 Free PMC article.
A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors.
van Not OJ, Wind TT, Ismail RK, Bhattacharya A, Jalving M, Blank CU, Aarts MJB, van den Berkmortel FWPJ, Boers-Sonderen MJ, van den Eertwegh AJM, de Groot JWB, Haanen JB, Kapiteijn E, Bloem M, Piersma D, van Rijn RS, Stevense-den Boer M, van der Veldt AAM, Vreugdenhil G, Wouters MWJM, Blokx WAM, Suijkerbuijk KPM, Fehrmann RSN, Hospers GAP. van Not OJ, et al. Cancers (Basel). 2023 May 26;15(11):2922. doi: 10.3390/cancers15112922. Cancers (Basel). 2023. PMID: 37296885 Free PMC article.
Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies.
Van Not OJ, van den Eertwegh AJM, Haanen JB, van Rijn RS, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Boers-Sonderen MJ, van Eijs MJM, de Groot JB, Hospers GAP, Kapiteijn E, de Meza M, Piersma D, Stevense-den Boer M, van der Veldt AAM, Vreugdenhil G, Wouters MWJM, Suijkerbuijk KPM, Blokx WAM. Van Not OJ, et al. Eur J Cancer. 2023 Jun;186:27-37. doi: 10.1016/j.ejca.2023.03.009. Epub 2023 Mar 16. Eur J Cancer. 2023. PMID: 37023588 Free article.
Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma.
van Duin IAJ, Elias SG, van den Eertwegh AJM, de Groot JWB, Blokx WAM, van Diest PJ, Leiner T, Verhoeff JJC, Verheijden RJ, van Not OJ, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Haanen JBAG, Hospers GAP, Kamphuis AM, Piersma D, van Rijn RS, van der Veldt AAM, Vreugdenhil G, Wouters MWJM, Stevense-den Boer MAM, Boers-Sonderen MJ, Kapiteijn E, Suijkerbuijk KPM. van Duin IAJ, et al. Among authors: van not oj. Int J Cancer. 2023 Jun 15;152(12):2493-2502. doi: 10.1002/ijc.34479. Epub 2023 Mar 4. Int J Cancer. 2023. PMID: 36843274
Adjuvant treatment of in-transit melanoma: Narrowing the knowledge gap left by clinical trials.
de Meza MM, Blokx WAM, Bonenkamp HJ, Blank CU, Aarts MJB, van den Berkmortel FWPJ, Boers-Sonderen MJ, de Groot JWB, Haanen JB, Hospers GAP, Kapiteijn EW, van Not OJ, Piersma D, van Rijn RS, Stevense-Den Boer MA, van der Veldt AAM, Vreugdenhil G, van den Eertwegh AJM, Suijkerbuijk KPM, Wouters MWJM. de Meza MM, et al. Among authors: van not oj. Int J Cancer. 2023 Jul 15;153(2):389-398. doi: 10.1002/ijc.34485. Epub 2023 Mar 8. Int J Cancer. 2023. PMID: 36843260
18 results